July 1, 2025 | Client News, NASDAQ: EZFL, NASDAQ: HTCR, NASDAQ: LASE, NASDAQ: MIGI, NASDAQ: OKYO, NASDAQ: SPRC, NYSE American: NNVC
Wattbike acquisition is the latest milestone in transformational strategy and the Sportstech acquisition is on track to close in the third quarter TRNR confirms guidance of more than $75 million in pro forma 2025 revenue and profitability in fourth quarter TRNR’s $55 million Digital Asset Treasury is actively purchasing $FET cryptocurrency AUSTIN, TX AND NOTTINGHAM, […]
July 1, 2025 | Client News, NASDAQ: EZFL, NASDAQ: HTCR, NASDAQ: LASE, NASDAQ: MIGI, NASDAQ: OKYO, NASDAQ: SPRC, NYSE American: NNVC
IRVINE, Calif., July 01, 2025 (GLOBE NEWSWIRE) — SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical”), a global franchise and provider of services for aesthetic clinics, is pleased to announce the appointment of Shinya Inoue as Chief Marketing Officer (CMO), effective July 1, 2025. As CMO of SBC Medical, Mr. Inoue will lead efforts […]
June 30, 2025 | Client News, NASDAQ: EZFL, NASDAQ: HTCR, NASDAQ: LASE, NASDAQ: MIGI, NASDAQ: OKYO, NASDAQ: SPRC, NYSE American: NNVC
Hinson brings a proven track record of driving growth and innovation in sales organizations BOCA RATON, FL / ACCESS Newswire / June 30, 2025 / Greenlane Holdings, Inc. (“Greenlane” or the “Company”) (Nasdaq:GNLN), one of the premier global sellers of premium cannabis accessories, child-resistant packaging, and specialty vaporization products, today announced the appointment of Mike Hinson as the […]
June 27, 2025 | Client News, NASDAQ: EZFL, NASDAQ: HTCR, NASDAQ: LASE, NASDAQ: MIGI, NASDAQ: OKYO, NASDAQ: SPRC, NYSE American: NNVC
Reaffirms Commitment to Transparency; No Immediate Plans to Utilize ATM or Shelf Registrations Scottsdale, AZ, June 27, 2025 (GLOBE NEWSWIRE) — CISO Global (NASDAQ: CISO), a leader in AI-powered cybersecurity software and compliance services, announced it has filed the renewal of its S-3 shelf registration, reducing the total shelf from $300 million to $100 million. The […]
February 28, 2025 | Client News, NASDAQ: EZFL, NASDAQ: HTCR, NASDAQ: LASE, NASDAQ: MIGI, NASDAQ: OKYO, NASDAQ: SPRC, NYSE American: NNVC
TRNR details $50M pro forma annual revenue guidance, rationale of expected Sportstech acquisition, comments on market manipulation concerns and bitcoin as a Treasury asset AUSTIN, TX / ACCESS Newswire / February 27, 2025 / Interactive Strength Inc. (Nasdaq:TRNR) (“TRNR” or the “Company”), maker of innovative specialty fitness equipment under the CLMBR and FORME brands, today […]
May 8, 2024 | Client News, NASDAQ: OKYO
LONDON and NEW YORK, May 08, 2024 (GLOBE NEWSWIRE) — OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA […]
April 30, 2024 | Client News, NASDAQ: OKYO
LONDON and NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) — OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA […]
April 9, 2024 | Client News, NASDAQ: OKYO
LONDON and NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) — OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA […]
April 2, 2024 | Client News, NASDAQ: OKYO
LONDON and NEW YORK, April 02, 2024 (GLOBE NEWSWIRE) — OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA […]
